Epoetin Alfa (EPO)
The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data
... with epoetin-alfa (EPO) and newer erythrocyte stimulating agents (ESA) has mitigated its severity, some recent studies have reported adverse outcomes of effective anemia correction with EPO and other ESAs ...
12
COST EFFECTIVENESS OF METHOXY POLYETHYLENE GLYCOLEPOETIN Β VERSUS EPOETIN ALFA IN THE TREATMENT OF HEMODIALYSIS PATIENTS WITH RENAL ANEMIA
... This study is a prospective single center randomized controlled open labeled clinical trial that was carried out at hemodialysis Unit, Baghdad Teaching Hospital from 1st October 2014 to 5th May 2015. Ethical Approval was ...
18
Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon<sup>®</sup> and Eprex<sup>®</sup> following a single subcutaneous administration in healthy male volunteers
... The RET count level did not directly correspond to the change in the serum EPO concentration, but showed a hys- teretic relationship. The plot of the serum EPO concentra- tion versus the RET count joined in the time ...
9
Feasibility of a Multiplex Flow Cytometric Bead Immunoassay for Detection of Anti-Epoetin Alfa Antibodies
... had epoetin alfa (EPO), sperm whale myoglobin (SWM; a negative control), or human IgG (IgG; a positive control) covalently attached to their surfaces by standard amine ...
8
Rituximab therapy for pure red cell aplasia due to anti epoetin antibodies in a woman treated with epoetin alfa: a case report
... The patient then received rituximab 375 mg/m 2 intrave- nously weekly for four doses with monthly IVIG 0.5 g/kg for 4 months starting at the time of rituximab therapy. Within 5 months, the reticulocyte count began to ...
5
Novel Approaches in Erythropoietin
... Erythropoietin, or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow. Also called hematopoietin or ...
14
A PROSPECTIVE AND OBSERVATIONAL STUDY OF USE AND FREQUENCY OF VARIOUS ERYTHROPOIETIN (EPO) CONGENERS AND ANALYSING THEIR EFFECTIVENESS IN THREE FORMS: DARBEPOETIN ALFA, EPOETIN ALPHA AND PEGYLATED ERYTHROPOIETIN ON DIALYSIS PATIENTS AT MAX SUPER SPECIALITY HOSPITAL, PATPARGANJ, DELHI
... Darbepoetin alfa, Epoetin alpha and Pegylated Erythropoietin, by calculating their hemoglobin level of the patient on ...Darbepoetin alfa (before and after 7.8 and 10.9), Epoetin alfa ...
6
Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis
... as epoetin alfa given thrice weekly (dialysis patients) or darbepoetin given once weekly (nondialysis patients), in correcting anemia of chronic kidney disease as well as maintaining hemoglobin within the ...
7
An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients
... from epoetin alfa to ...agents. Epoetin alfa-induced reti- culocytosis (the pharmacodynamic effect) peaks approxi- mately 1 to 2 weeks after administration [11], substantially beyond its ...
10
Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
... of epoetin-beta with epoetin-alfa or darbepoetin these agents are considered by regulatory agencies and professional bodies as belonging to a single class without signifi cant difference in ...
10
HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
... European Medicines Agency (EMA). The decision to approve a biosimilar is based on the totality of evidence obtained in a comprehensive comparability exercise that involves extensive analytical characterization, ...
6
Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
... Inclusion criteria included patients at least 18 years of age presenting with CIA (irrespective of chemotherapy cycle) associated with solid tumors, lymphomas, or myelomas and eligible for treatment with an ...
5
Hemoglobin Level Stability after a Switch from Darbepoetin Alfa to Epoetin Beta Pegol for the Treatment of Renal Anemia in Hemodialysis Patients
... Dalbepoetin alfa (DA) has a much longer half-life and longer erythropoietic effect than epoetin alfa [6] ...of epoetin alfa per 1 μg of DA ...
9
Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
... The mean overall hemoglobin at the end of the study was 10.8 g/dL. There were no significant differences (P.0.05) between the different treatment groups in terms of hemoglobin level at the start of ESA treatment, ...
6
Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
... from epoetin alfa to darbepoetin alfa in October 2007 (index date) who had been on hemodialysis for at least 15 months before the index date and remained on hemodialysis for at least 24 months after ...
7
Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C:a retrospective study using the Japanese Interferon Database
... PEG-IFN alfa-2a and alfa-2b, using a t-test for age, the Wilcoxon rank-sum test for duration of therapy, the Mantel–Haenszel chi-square statistic for genotype, and the chi-square test for the other ...
8
4795.pdf
... offer support and relief to those who needed it. The category “Non-Fiction—Lesbian” highlighted Love Between Women, by Charlotte Wolff (1971); Lesbian/Woman, by Del Martin and Phyllis Lyon (1972); Sappho Was a Right-On ...
318
Effect of Blending Ratio of Fibers on the Properties of Nonwoven Fabrics Based of Alfa Fibers
... the Alfa fibers ratio, to the machine direction and the cross ...of Alfa fibers exceeds that of the used fibers, we notice that increasing the Alfa fibers ratio de- creases the nonwoven elongation at ...
10
The safety profile of drotrecogin alfa (activated)
... Drotrecogin alfa (activated; DrotAA) is the first and thus far only compound proven to improve survival in patients with severe sepsis. The mechanisms that underlie the improved survival are not entirely clear. A ...
8
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
... agalsidase alfa, and that early intervention with ERT when cardiac or myocardial dysfunction is still mild, may prevent the progression to subsequent cardiac failure and improve cardiac involve- ment of FD ...
9